Titre :
  • Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Auteur : Dowsett, Mitch ; Procter, Marion ; McCaskill-Stevens, Worta ; Azambuja, Evandro ; Dafni, U ; Rueschoff, J. ; Jordan, B. ; Dolci, Stella ; Abramovitz, Mark ; Stoss, Oliver ; Viale, G ; Gelber, R D ; Piccart-Gebhart, Martine ; Leyland-Jones, Brian
Informations sur la publication : Journal of clinical oncology, 27, 18, (page 2962-2969)
Statut de publication : Publié, 2009-06
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Antibodies, Monoclonal -- therapeutic use
Antineoplastic Agents -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- genetics
Breast Neoplasms -- mortality
Disease-Free Survival
Female
Gene Amplification
Genes, erbB-2
Humans
Immunohistochemistry
Prognosis
Note : Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0732-183X 
info:doi/10.1200/JCO.2008.19.7939
info:pii/JCO.2008.19.7939
info:pmid/19364966